August 2012
-
Inhaler testing equipment company Copley Scientific has entered into distribution agreements with companies in Turkey and Brazil and now has a Chinese sales and technical support representative in Nanjing, China. Copley sells a range of… Read more . . .
-
Submit abstracts online at www.ddl-conference.co.uk by July 27, 2012. View complete abstract guidelines. Read more . . .
-
Texas-based biotechnology company Pulmotect has been granted an award of $7.1 million by the Cancer Prevention & Research Institute of Texas (CPRIT) for development of its lead product PUL-042, an inhaled immune stimulant composed of… Read more . . .
-
As Medical Propellants Business Expert at Mexichem over the last 20+ years, Tim Noakes has developed unique access to and insight into pressurized metered dose inhaler manufacturing around the world. Read more . . . Read more . . .
-
PPD. This position is located in RTP, NC. This position involves conducting complex bioanalytical method and technology research and development projects to include the development and implementation of new assay methods, enhancement of existing methods,… Read more . . .
-
AstraZeneca has announced results of a study showing that the safety profile of Symbicort budesonide/formoterol inhalation aerosol 320/9 µg twice daily was similar to that for a budesonide alone pMDI 320 µg twice daily in… Read more . . .
-
The non-profit patient education organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) has announced the winners of its 2012 Top Ten Innovations in Technology Awards for “products and services that have meaningfully improved quality… Read more . . .
-
Melbourn Scientific is now offering powder characterization services using the Freeman Technology FT4 Powder Rheometer to optimize formulation and analysis services for inhaled drug and device development. Melbourn Scientific Operations Director Derek Solomon commented, “A… Read more . . .
-
Covance, Harrogate, UK, is currently seeking an Analytical Chemist with inhalation experience to join theChemistry, Manufacturing and Control – Pharmaceutical Development Services group. Successful candidates will be part of our exciting and expanding future, working… Read more . . .
-
Lightlake Therapeutics has announced preliminary results from a Phase 2 trial of its intranasal naloxone for the treatment of patients with binge eating disorder. According to the company, the randomized, double-blind, placebo-controlled trial demonstrated that… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland